Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why

3 Absurdly Cheap Stocks That Pay High Dividends

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead and MSD to advance once-weekly HIV treatment to Phase III

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48